ArticleCureus2025
Factors Associated With Mortality in Leukemia and Lymphoma With COVID-19: A National Inpatient Sample Analysis (2020-2021).
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Patients with hematological malignancies face a substantially increased mortality from COVID-19. Although the peak of the COVID-19 pandemic has passed, the virus remains common, and understanding its impact on vulnerable groups such as those with hematologic malignancies remains crucial. Limited research exists on mortality patterns in leukemia and lymphoma patients during the pandemic. Studying these outcomes provides important insights into how different waves of COVID-19 affected immunocompromised individuals and supports the development of strategies for prevention, patient care, and risk reduction, which are essential both for managing emerging variants and preventing future pandemics. We aimed to identify the mortality risk of COVID-19 in leukemia (LekCov-19) and lymphoma (LymCov-19) in the United States and the mortality trends between each quartile from 2020 to 2021. Methods We analyzed the National Inpatient Sample database (2020-2021) to include adults (≥18 years) having leukemia and lymphoma admitted for COVID-19. Descriptive analysis, propensity matching, and multivariate regression were performed, with the p-value at ≤0.05 considered statistically significant. The risk of mortality was compared between each outcome. Results Among 8,191 LekCov-19 patients, 1,200 (14.7%) experienced mortality, whereas 507 out of 2,578 LymCov-19 patients (19.7%) experienced mortality. Multivariate regression showed a two-fold increase in mortality among LekCOV-19 and LymCOV-19 (p < 0.001). In both cohorts, several organ dysfunctions, including pulmonary, renal, and cardiac dysfunctions, were associated with increased mortality (p ≤ 0.0001). Similarly, in both cohorts, signs of bone marrow dysfunction, such as pancytopenia and thrombocytopenia, showed increased odds of mortality (p < 0.01). Both cohorts exhibited varying mortality trends, peaking during October-December 2020, January-March, July-September, and October-December 2021 (p ≤ 0.01). Hematopoietic stem cell transplantation recipients had lower odds of mortality in both cohorts, but did not attain statistical significance (p > 0.05). Conclusion COVID-19 was associated with increased mortality in leukemia and lymphoma patients. Surges in COVID-19-related mortality were identified from October 2020 to March 2021, and these trends could be pivotal in forecasting future mortality risks in cancer patients. Clinicians should refine treatment regimens and prioritize advancing clinical trials to address the effects of COVID-19 and the multiple comorbidities associated with hematological malignancies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.